{
  "abstract": "We read with great interest the editorial by Eriksson and Midlöv, which rightly underscores the persistent challenge of medication adherence and the potential impact of effective medication adherence-enhancing interventions (MAEIs) on population health, healthcare costs and clinical outcomes.1 Despite decades of awareness and growing technological promise, the translation of MAEIs into scalable, reimbursable and evidence-based practice remains relatively limited.",
  "authors": [
    {
      "affiliations": [
        "Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka Faculty of Medicine, Rijeka, Croatia"
      ],
      "name": "Andrej Belančić"
    },
    {
      "affiliations": [
        "Department of Pathophysiology, University of Sarajevo, Sarajevo, Bosnia and Herzegovina"
      ],
      "name": "Almir Fajkić"
    },
    {
      "affiliations": [
        "Sestre Milosrdnice University Hospital Center, Catholic University of Croatia, Zagreb, Croatia"
      ],
      "name": "Ines Potočnjak"
    }
  ],
  "title": "Why are we still overlooking adherence in clinical trials? A call to extend medication adherence-enhancing interventions and monitoring beyond real-world practice",
  "uid": "e43a9ed4-753f-5367-8437-f7a96f0f3b43"
}